At a glance
- Secretin (human/porcine) is an FDA-approved drug, marketed as Porcine, Chirhostim (first approval: April 4, 2002).
- PubMed lists 2,616 publications mentioning it, including 96 randomized controlled trials and 1,021 animal-only studies.
- ClinicalTrials.gov lists 53 registered studies testing it (12 active).
- FDA's adverse event system (FAERS) holds 16 reports mentioning it; 14 classified as serious. Reports do not prove causation.
Research topics
Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).
Regulatory status
Drugs@FDA applications
| Application | Product | Status | First approval | Sponsor |
|---|---|---|---|---|
| NDA021136 | SECREFLO | Approved, discontinued | April 4, 2002 | CHIRHOCLIN |
| NDA021209 | PORCINE SECRETIN | Approved, marketed | April 4, 2002 | CHIRHOCLIN |
| NDA021256 | CHIRHOSTIM | Approved, marketed | April 9, 2004 | CHIRHOCLIN |
| NDA018290 | SECRETIN-FERRING | Approved, discontinued | — | FERRING |
Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query
FDA compounding safety list
Not on FDA's list of bulk drug substances that may present significant safety risks in compounding.
Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026
Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.
Scientific publications
Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.
Latest publications
- Endoscopic ultrasound in the diagnosis of chronic pancreatitis: a structured state-of-the-art review.
- Osteopathic manipulative treatment as an adjunct therapy in a pediatric patient with chronic pancreatitis and visceral hyperalgesia: a case report.
- Extensive polycystic pancreas in a child: A rare congenital lesion.
- Spontaneous Bacterial Peritonitis as a Rare Complication of a Pancreatic Duct Leak in a Patient Without Cirrhosis: A Case Report.
- Pancreatic Fluid Enzymes as a Functional Chronic Pancreatitis Biomarker: A Pilot Endoscopic Study.
- Recurrent acute pancreatitis caused by a duodenal diverticulum: The diagnostic value of secretin-enhanced magnetic resonance cholangiopancreatography.
- The mechanistic role of secretin and its receptor in regulating hippocampal dentate gyrus glutamatergic neuronal activity in methamphetamine addiction.
- Effects of Glucagon-Like Peptide 1, Glucagon, and Glucose-Dependent Insulinotropic Polypeptide on Fluid Secretion in Guinea-Pig Pancreatic Duct Cells.
- Function Regulation Assessment and Pathophysiological Dysfunction Repair of Oddi Sphincter.
- From bench to bedside: pancreatic juice as a platform for biomarker discovery in pancreatic disease.
Source: PubMed (NCBI) · verified October 30, 2026
Clinical trials
- Registered
- 53
- Active
- 12
- With posted results
- 8
Conditions studied
Show 40 more studies
All 53 studies on ClinicalTrials.gov ↗
Source: ClinicalTrials.gov · verified October 30, 2026
Adverse event reports
- Reports
- 16
- Serious
- 14
- With death outcome
- 0
Most reported reactions
Adverse event reports do not prove that the substance caused these effects. Side effects not listed here may still occur. Reaction terms are MedDRA terms as reported to FAERS.
Source: FDA FAERS (FAERS data as of July 30, 2026) · verified October 30, 2026 · API query
FDA prescribing information
Official US prescribing information. Dosing sections are intentionally not shown.
- Digestive Enzyme Drops 2018
- Secretin Cycle II Drops 2164
- Secretin Cycle I Drops 2163
- ChiRhoStim, ChiRhoStim 40
Source: DailyMed / openFDA
Change history
No changes since monitoring began on October 30, 2026.